Abstracts tagged "Fibromyalgia and medication"

Abstract Number: 256 • 2018 ACR/ARHP Annual Meeting
The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
Robert S. Katz, Rush University Medical Center, Chicago, IL
Background/Purpose: We asked patients with fibromyalgia to rank the effectiveness of medications they have tried. Methods: In a rheumatology office practice, 95 patients (mean age…
Abstract Number: 161 • 2017 ACR/ARHP Annual Meeting
The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
Robert S. Katz and Frank Leavitt, Rush University Medical Center, Chicago, IL
Background/Purpose: To assess patients’ global assessment of frequently used treatments for the fibromyalgia syndrome (FMS), we asked patients with fibromyalgia to rank medications they have…
Abstract Number: 1105 • 2013 ACR/ARHP Annual Meeting
New and Not Improved? The Efficacy Of FMS Medications
Robert S. Katz¹, Hannah Bond², Lauren Kwan², Jessica L. Polyak² and Susan Shott³, ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: A wide variety of medications are used to treat FMS, with an equally wide variety of opinions about their efficacy. We asked FMS…
Abstract Number: 1863 • 2012 ACR/ARHP Annual Meeting
Resetting the Naming Speed Clock with Methylphenidate (Ritalin)
Robert S. Katz and Frank Leavitt, Rush University Medical Center, Chicago, IL
Background/Purpose: Abnormalities in naming speed are an unappreciated feature of cognitive dysfunction in fibromyalgia (FMS). Approximately 50% of FMS patients with memory problems name words…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].